A significative decrease in angiogenesis, determined by a reduction of the area occupied by CD31+ cells in the tumor/peritumor areas, was observed in mice treated with guadecitabine/ICBs compared to guadecitabine or ICBs alone (Fig. 9H). Here, PECAM1 is linked to neoplasm.